总时间（秒）：20.74
问答时间（秒）：19.09

Based on the provided literature, I will extract and standardize the required information according to the predefined JSON framework.

**Variants Include**

* Gene: SNCA (alpha-synuclein)
* Variants:
	+ HGVS: NM_000345.4:c.56-102del
	+ cDNA Change:
		- Transcript: NM_000345.4
		- Ref: N/A
		- Alt: del
		- Position: 56-102
	+ Protein Change: Not mentioned in the literature
	+ Description in input context: Deletion of residues 56-102 (exon 4) decreases PLD2 inhibition significantly.

**Variants Include**

* Gene: SNCA (alpha-synuclein)
* Variants:
	+ HGVS: NM_000345.4:c.*130-140del
	+ cDNA Change:
		- Transcript: NM_000345.4
		- Ref: N/A
		- Alt: del
		- Position: 130-140
	+ Protein Change: Not mentioned in the literature
	+ Description in input context: Deletion of C-terminal residues 130-140 (exon 6) completely abolishes inhibitory activity.

**Variants Include**

* Gene: SNCA (alpha-synuclein)
* Variants:
	+ HGVS: NM_000345.4:s129phos
	+ cDNA Change:
		- Transcript: NM_000345.4
		- Ref: A
		- Alt: P
		- Position: 129
	+ Protein Change: Not mentioned in the literature
	+ Description in input context: Phosphorylation at serine 129 blocks PLD2 inhibition.

**Variants Include**

* Gene: SNCA (alpha-synuclein)
* Variants:
	+ HGVS: NM_000345.4:y125phos
	+ cDNA Change:
		- Transcript: NM_000345.4
		- Ref: T
		- Alt: P
		- Position: 125
	+ Protein Change: Not mentioned in the literature
	+ Description in input context: Phosphorylation at tyrosine 125 blocks PLD2 inhibition.

**Variants Include**

* Gene: SNCA (alpha-synuclein)
* Variants:
	+ HGVS: NM_000345.4:y136phos
	+ cDNA Change:
		- Transcript: NM_000345.4
		- Ref: A
		- Alt: P
		- Position: 136
	+ Protein Change: Not mentioned in the literature
	+ Description in input context: Phosphorylation at tyrosine 136 blocks PLD2 inhibition.

**Described Disease**

* Described Disease: Parkinson's disease (PARK1)
* MONDO: MONDO:0005146

**Experiment Method**

* Assay Method: In vitro assay
* Material used:
	+ Material Source: SNCA gene expression system
	+ Material Name: N/A
	+ Description: N/A
* Readout type: Quantitative
* Readout description: Not mentioned in the literature
* Biological replicates:
	+ Biological replicates: Yes
	+ Description: N/A
* Technical replicates:
	+ Technical replicates: No
	+ Description: N/A
* Basic positive control:
	+ Basic positive control: Yes
	+ Description: Wild-type SNCA cDNA was used as a positive control.
* Basic negative control:
	+ Basic negative control: Yes
	+ Description: Empty vector was used as a negative control.
* Validation controls P/LP:
	+ Validation controls P/LP: No
	+ Counts: N/A
* Validation controls B/LB:
	+ Validation controls B/LB: No
	+ Counts: N/A
* Statistical analysis method:
	+ Statistical analysis method: N/A
* Threshold for normal readout:
	+ Threshold for normal readout: N/A
	+ Source: Literature
* Threshold for abnormal readout:
	+ Threshold for abnormal readout: N/A
	+ Source: Literature
* Approved assay:
	+ Approved assay: No

The final JSON output is as follows:

```
{
    "Variants Include": [
        {
            "Gene": "SNCA",
            "variants": [
                {
                    "HGVS": "NM_000345.4:c.56-102del",
                    "cDNA Change": {
                        "transcript": "NM_000345.4",
                        "ref": "N/A",
                        "alt": "del",
                        "position": "56-102"
                    },
                    "Protein Change": "",
                    "Description in input context": "Deletion of residues 56-102 (exon 4) decreases PLD2 inhibition significantly."
                },
                {
                    "HGVS": "NM_000345.4:c.*130-140del",
                    "cDNA Change": {
                        "transcript": "NM_000345.4",
                        "ref": "N/A",
                        "alt": "del",
                        "position": "130-140"
                    },
                    "Protein Change": "",
                    "Description in input context": "Deletion of C-terminal residues 130-140 (exon 6) completely abolishes inhibitory activity."
                }
            ]
        }
    ],
    "Described Disease": {
        "Described Disease": "Parkinson's disease (PARK1)",
        "MONDO": "MONDO:0005146"
    },
    "Experiment Method": [
        {
            "Assay Method": "In vitro assay",
            "Material used": {
                "Material Source": "SNCA gene expression system",
                "Material Name": "N/A",
                "Description": "N/A"
            },
            "Readout type": "Quantitative",
            "Readout description": [],
            "Biological replicates": {
                "Biological replicates": "Yes",
                "Description": "N/A"
            },
            "Technical replicates": {
                "Technical replicates": "No",
                "Description": "N/A"
            },
            "Basic positive control": {
                "Basic positive control": "Yes",
                "Description": "Wild-type SNCA cDNA was used as a positive control."
            },
            "Basic negative control": {
                "Basic negative control": "Yes",
                "Description": "Empty vector was used as a negative control."
            },
            "Validation controls P/LP": {
                "Validation controls P/LP": "No",
                "Counts": "N/A"
            },
            "Validation controls B/LB": {
                "Validation controls B/LB": "No",
                "Counts": "N/A"
            },
            "Statistical analysis method": {
                "Statistical analysis method": "N/A"
            },
            "Threshold for normal readout": {
                "Threshold for normal readout": "N/A",
                "Source": "Literature"
            },
            "Threshold for abnormal readout": {
                "Threshold for abnormal readout": "N/A",
                "Source": "Literature"
            },
            "Approved assay": {
                "Approved assay": "No"
            }
        }
    ]
}
```